Amplification of epidermal growth factor receptor (EGFR) and its active mutant EGFRvIII
occurs frequently in glioblastoma (GBM). While EGFR and EGFRvIII play critical roles in …

Several mechanisms have been proposed for histone marks to exert their functions,
including altering the physical properties of nucleosomes by neutralization of charge via …

Pancreatic ductal adenocarcinoma (PDAC) is almost uniformly fatal and characterized by
early metastasis. Oncogenic KRAS mutations prevail in 95% of PDAC tumors and co-occur …

Epithelial mesenchymal transition (EMT) is a reversible developmental genetic programme
of transdifferentiation of polarised epithelial cells to mesenchymal cells. In cancer, EMT is an …

Mutations that decrease or increase the activity of the tyrosine phosphatase, SHP2 (encoded
by PTPN11), promotes developmental disorders and several malignancies by varying …

Aberrant glycosylation is a universal feature of cancer cells and there is now overwhelming
evidence that glycans can modulate pathways intrinsic to tumour cell biology. Glycans are …

More than half of cancer patients receive radiotherapy as a part of their cancer treatment.
DNA double-strand breaks (DSBs) are considered as the most lethal form of DNA damage …

Genomic analyses have revealed mutational footprints associated with DNA maintenance
gone awry, or with mutagen exposures. Because cancer therapeutics often target DNA …

Type I interferon (IFN-α/β or IFN-I) signals through two receptor subunits, IFNAR1 and
IFNAR2, to orchestrate sterile and infectious immunity. Cellular pathways that regulate …

The serine/threonine kinase AKT, also known as protein kinase B (PKB), is the major
substrate to phosphoinositide 3-kinase (PI3K) and consists of three paralogs: AKT1 (PKBα) …